# International Cooperative Phase III Trial of the HIT-HGG Study Group (HIT-HGG-2013)

> **NCT03243461** · PHASE3 · UNKNOWN · sponsor: **University of Göttingen** · enrollment: 167 (estimated)

## Conditions studied

- Glioblastoma WHO Grade IV
- Diffuse Midline Glioma Histone 3 K27M WHO Grade IV
- Anaplastic Astrocytoma WHO Grade III
- Diffuse Intrinsic Pontine Glioma
- Gliomatosis Cerebri

## Interventions

- **DRUG:** Temozolomide + Valproic Acid

## Key facts

- **NCT ID:** NCT03243461
- **Lead sponsor:** University of Göttingen
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2018-07-17
- **Primary completion:** 2023-12-31
- **Final completion:** 2023-12-31
- **Target enrollment:** 167 (ESTIMATED)
- **Last updated:** 2022-06-06

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03243461

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03243461, "International Cooperative Phase III Trial of the HIT-HGG Study Group (HIT-HGG-2013)". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT03243461. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*